(Q46209083)

20 December 2017

title

Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma (English)

1 reference

20 December 2017

1 reference

Funda Corapcioglu

1

1 reference

20 December 2017

Hatice Mutlu

2

1 reference

20 December 2017

Bülent Kara

3

1 reference

20 December 2017

Nagihan Inan

4

1 reference

20 December 2017

Gür Akansel

5

1 reference

20 December 2017

Yesim Gürbüz

6

1 reference

20 December 2017

Salih Topcu

7

1 reference

20 December 2017

publication date

1 December 2008

1 reference

20 December 2017

Pediatric Hematology and Oncology

published in

1 reference

20 December 2017

volume

25

1 reference

20 December 2017

issue

8

1 reference

20 December 2017

page(s)

756-761

1 reference

20 December 2017

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08880010802341690

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880010802341690

Correspondence: treatment of the neuroblastoma-associated opsoclonus-myoclonus-ataxia (OMA) syndrome with high-dose methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880010802341690

Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880010802341690

21 January 2018

An update on opsoclonus

1 reference

https://api.crossref.org/works/10.1080%2F08880010802341690

Long-term outcome of ten children with opsoclonus-myoclonus syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880010802341690

10.1080/08880010802341690

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017